Evaluation of pentisomide on stable ventricular premature beats. Comparison with placebo

S. G. Mangini, F. Mastropasqua, V. Oldani, F. Massari, G. N. Mainio, A. Ricci, D. Scrutinio, P. Rizzon

Research output: Contribution to journalArticlepeer-review


Pentisomide, a new class I anti-arrhythmic drug, was compared to placebo in 50 hospitalized patients with frequent (>30 h-1) and stable ventricular premature beats (VPB) (variation less than 50% between two preliminary and one placebo 24-h Holter recordings). All patients underwent a single-dose acute oral testing followed by a short-term testing with 300 mg t.i.d. for 4 days and then by a 4-day placebo period. For the studied population, a 56.4% reduction of simple VPB and a 98.8% decrease of couplets and runs were the minimum required to define the drug efficacy and to exclude spontaneous variability, using the linear regression analysis. Pentisomide was found effective in 27 (54%) of the 50 patients after the acute test and in 23 (46%) after the short-term test. The drug induced a mild increase of PR and QRS intervals, while QTc, heart rate, blood pressure and ejection fraction showed no significant variations. Subjective tolerability was excellent.

Original languageEnglish
Pages (from-to)712-719
Number of pages8
JournalEuropean Heart Journal
Issue number6
Publication statusPublished - 1991


  • Acute test
  • Pentisomide
  • Short-term test
  • Spontaneous variability
  • Ventricular premature beats

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Evaluation of pentisomide on stable ventricular premature beats. Comparison with placebo'. Together they form a unique fingerprint.

Cite this